跳至主要内容
临床试验/NCT02326051
NCT02326051已完成4 期

Timing of Initiation of Low Molecular Weight Heparin Administration in Pregnant Women With Antiphospholipid Syndrome

Mohamed Sayed Abdelhafez2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100
试验地点
2
主要终点
Ongoing pregnancy rate

研究概览

简要总结

Evaluation of the effect of altering the timing of initiation of low molecular weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS)

详细描述

Women will be randomly divided into two groups; one will start Enoxaparin therapy once positive pregnancy test is established and the other will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation. In all women, Enoxaparin will be given in a dose of 40 mg/day subcutaneously and the therapy will continue until termination of pregnancy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
20 Years 至 38 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women with APS diagnosed according to the revised classification criteria for APS in 2006 in Sydney, Australia
  • Early pregnancy body weight is 50-90 Kg

排除标准

  • Women with systemic lupus erythematosus (SLE)
  • Women with active thromboembolic disorders
  • Women with history of previous thromboembolic disorders

研究组 & 干预措施

Early Enoxaparin initiation

Active Comparator

Women will start Enoxaparin therapy once positive pregnancy test is established

干预措施: Enoxaparin (Drug)

Later Enoxaparin initiation

Active Comparator

Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation

干预措施: Enoxaparin (Drug)

结局指标

主要结局

Ongoing pregnancy rate

时间窗: After 12 weeks gestational age

Number of pregnancies that progressed beyond the critical first trimester (12 weeks gestational age) per number of pregnant women

次要结局

  • Fetal loss(From 20 weeks to 42 weeks gestational age)
  • Preterm delivery(From 20 weeks to 34 weeks gestational age)
  • Congenital fetal malformations(At birth)
  • Intrauterine growth restriction (IUGR)(At birth)

研究者

发起方
Mohamed Sayed Abdelhafez
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mohamed Sayed Abdelhafez

Dr

Mansoura University

研究点 (2)

Loading locations...

相似试验